RxDoctor Payments Data

Sean McCarthy, MD

Dermatology · Greensboro, NCNPI 1952581019

Payments from drug & device makers

$8,601in general payments, 2019–2025

Across 366 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Regeneron Healthcare Solutions, Inc.$602
  • Amgen$545
  • Sanofi$500
  • Johnson & Johnson$489
  • E.r. Squibb & Sons, L.L.C.$424
  • plus $2K from 15 others

What the payments were for

  • Consulting fees$1,83821%
  • Food & beverage$6,56476%
  • Education$1992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,601 in reported general payments places this provider in the 75th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$136,323
Medicare patients
532
Services billed
1,806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa24$507,486
Dupixent PenDupilumab60$223,279
OtezlaApremilast13$57,332
Dupixent SyringeDupilumab13$47,890
AdbryTralokinumab-Ldrm11$43,069
Clobetasol Propionate275$10,637
Fluorouracil89$6,983
Triamcinolone Acetonide226$2,636
Fluocinolone AcetonideFluocinolone/Shower Cap36$2,525
Doxycycline Hyclate106$1,940
Metronidazole28$1,267
Tretinoin14$834
Ketoconazole38$460
Fluocinolone Acetonide15$444
ValacyclovirValacyclovir Hcl15$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$545$57,33213 claims
LEO Pharma Inc.Adbry$236$43,06911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →